Expression And Scoring Of HER2/Neu in Variants of Prostate Adenocarcinoma
DOI:
https://doi.org/10.51985/JBUMDC2019125Keywords:
Adenocarcinoma Prostate, Acinar, Ductal, Gleason Groups, PSA levels, Variants, HER2/neu.Abstract
Objective: To evaluate the immunohistochemical expression and scoring of HER2/neu in different variants of adenocarcinoma
of prostate and to compared the association of HER2/neu expression with biological behavior and risk factors of prostate
adenocarcinoma.
Study Design and Setting: Cross sectional study in which all clinically suspected prostate adenocarcinoma cases received
at the laboratory Saddar Karachi during the years 2015 and 2016 were evaluated for morphological features of adenocarcinoma.
Methodology: This cross sectional study was carried out using prostate biopsies of clinically suspected prostate
adenocarcinoma. The diagnosis of adenocarcinoma was confirmed and histological characterization was done by evaluating
the morphological features. The tumors were graded according to the revised 2015 Gleason’s grouping. Immunohistochemical
analysis for HER2/neu expression was performed in the most representative tumor block. SPSS version 22 was used for
data analysis. Mean frequency and percentages were calculated for quantitative variables, whereas chi-square test and
Fisher’s Exact Test were applied for qualitative variables. P-value of < 0.05 was considered as significant.
Results: Out of 77 biopsies only one showed moderate HER2/neu expression. Positive HER2/neu was acinar variant. No
significant statistical association was observed between expression of HER2/neu and prostate cancer variants. The positive
case had age more than 60 years with moderately increased serum PSA levels and was aggressive in nature at the time of
diagnosis.
Conclusion: It was concluded from the study that HER2/neu was rarely expressed in prostate adenocarcinoma.
References
Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta gene. 2014;2:596-605.
Appleton L, Wyatt D, Perkins E, Parker C, Crane J, Jones A, et al. The impact of prostate cancer on men's everyday life.
European journal of cancer care. 2015;24(1):71-84.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal
A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
countries. CA: a cancer journal for clinicians. 2018;68(6):394- 424.
Jhan J-H, Yang Y-H, Chang Y-H, Guu S-J, Tsai C-C. Hormone therapy for prostate cancer increases the risk of Alzheimer’s
disease: a nationwide 4-year longitudinal cohort study. The Aging Male. 2017;20(1):33-8.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal
for clinicians. 2015;65(2):87-108.
Idrees R, Fatima S, Abdul-Ghafar J, Raheem A, Ahmad Z. Cancer prevalence in Pakistan: meta-analysis of various
published studies to determine variation in cancer figures resulting from marked population heterogeneity in different
parts of the country. World journal of surgical oncology. 2018;16(1):129.
Gómez-Acebo I, Dierssen-Sotos T, Fernandez-Navarro P Palazuelos C, Moreno V, Aragonés N, et al. Risk model for
prostate cancer using environmental and genetic factors in the spanish multi-case-control (MCC) study. Scientific reports.
;7(1):8994.
Ricke EA, Williams K, Lee Y-F, Couto S, Wang Y, Hayward SW, et al. Androgen hormone action in prostatic carcinogenesis:
stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.
Carcinogenesis. 2012;33(7):1391-8.
Martins T, Ukoumunne OC, Banks J, Raine R, Hamilton W. Ethnic differences in patients’ preferences for prostate cancer
investigation: a vignette-based survey in primary care. Br J Gen Pract. 2015;65(632):e161-e70.
Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU
international. 2002;89(6):538-42.
Kalantari MR, Mahdavi Zafarghandi R, Tavakkoli M, Kalantari S, Aghaee A, Mirsani A, et al. Relation between HER-2 gene
expression and prognostic prostate cancer parameters in trus guided biopsies. Journal of Patient Safety & Quality
Improvement. 2019;7(2):69-74.
Miller DR, Ingersoll MA, Lin M-F. ErbB-2 signaling in advanced prostate cancer progression and potential therapy.
Endocrine-Related Cancer. 2019;1(aop). 13. Ajetunmobi O, Drebber U, Buettner R, Dzuachii O, Vhritherire
R, Oguntunde O, et al. Expression of HER Receptor Proteins in Prostate Adenocarcinoma: A Perspective from North Central
Nigeria. Open Journal of Pathology. 2019;9(03):58.
Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, et al. Androgen-dependent regulation of Her-2/neu in
prostate cancer cells. Cancer research. 2006;66(11):5723-8. 15. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK,
Wurm C, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget.
;10(41):4213. 16. Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann
J, Mirlacher M, et a l. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor
prognosis in prostate cancer.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Santosh Kumar Sidhwani, Madeeha Sadiq, Mubina Lakhani, Summaya Shawana, Raffia Siddiqui, Sobia Hassan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
